Inhibition of STAT3 activation can also lead to the inhibition of AKT activation (Chen et al., 2013), which also reflected our in vitro and in vivo findings, indicating multiple potential pathways for the anti-cancer activity of brevilin A. Here, AKT1 is linked to cancer.